Celyad Oncology S.A.

For H1 2023, Celyad reported R&D expenses of EUR 2.1 million versus EUR 10.5 million in H1 2022, G&A expenses of EUR 3.7 million versus EUR 6.2 million, net other income of EUR 2.1 million versus EUR 1.6 million, net loss of EUR 3.7 million, or EUR 0.17 per share, versus a net loss of EUR 14.1 million, or EUR 0.62 per share, and net cash used in operations of EUR 8.3 million versus EUR 16.3 million. Cash and cash equivalents were EUR 5 million as of June 30, 2023. Management also said it had received EUR 9.8 million in private placement commitments and expects existing cash plus that financing to fund operating expenses and capex until the end of Q4 2024.

George Rawadi framed the company as firmly in a post-restructuring phase focused on next-generation CAR T development and on maximizing its proprietary engineering platform, targets, and IP. He highlighted the strategic shift begun in 2022, the recent appointment of management, and the financing commitments as support for the company’s plan to push toward clinical evaluation either internally or through partnerships. His tone was confident and forward-looking, with repeated emphasis on the company’s mission and the value of its scientific portfolio.

David Georges focused on the cost reset and cash runway. He said R&D fell because the company discontinued manufacturing and some preclinical and clinical programs, while lower employee expense reflected headcount reductions; G&A also declined due to lower insurance costs and reduced employee expense from headcount and management changes. He noted no change in fair value of contingent consideration and other financial liabilities because no triggering events had made the probability of payment less remote, and said the company ended June with EUR 5 million in cash and cash equivalents.

There was no analyst Q&A; the operator said there were no questions. As a result, no external concerns were raised live, and management did not have to answer follow-up questions about the strategy, the financing, or the program timelines.